Keratoacanthoma - Cheratoacantoma
☆ Nei risultati della Stiftung Warentest 2022 dalla Germania, la soddisfazione dei consumatori con ModelDerm è stata solo leggermente inferiore rispetto alle consulenze di telemedicina a pagamento.
Tipico Cheratoacantoma (Keratoacanthoma)
References
Keratoacanthoma (KA) è un tumore cutaneo frequente noto per la sua rapida crescita e la capacità di regredire da solo. Si verifica tipicamente negli uomini più anziani, dalla pelle chiara con una storia di danni solari. Sebbene la rimozione chirurgica mediante escissione o chirurgia micrografica di Mohs sia il trattamento abituale, sono disponibili varie altre opzioni terapeutiche.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) è un tumore di basso grado che origina in alcune ghiandole della pelle e al microscopio appare simile a squamous cell carcinoma (SCC) . È in corso un dibattito sulla questione se la KA debba essere classificata come una forma di SCC invasivo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) è il secondo tipo di cancro più comune nelle persone, soprattutto tra gli anziani. La chirurgia viene generalmente utilizzata per trattare il cSCC, ma per alcuni pazienti che non possono sottoporsi a un intervento chirurgico o scelgono di non farlo, possono essere prese in considerazione altre opzioni come i trattamenti intralesionali. Sono stati utilizzati trattamenti intralesionali tradizionali (methotrexate or 5-fluorouracil) , ma è in corso la ricerca su nuovi approcci come l'immunoterapia intralesionale e la viroterapia oncolitica. Qui esamineremo diversi trattamenti intralesionali per cSCC, dai metodi classici alle strategie all'avanguardia.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Al microscopio, il cheratoacantoma (keratoacanthoma) ricorda molto da vicino il carcinoma a cellule squamose. Mentre alcuni patologi classificano il cheratoacantoma (keratoacanthoma) come un'entità distinta e non un tumore maligno, circa il 6% dei cheratoacantoma (keratoacanthoma) clinici e istologici progredisce verso tumori a cellule squamose invasivi e aggressivi.
○ Diagnosi e trattamento
#Dermoscopy
#Skin biopsy